Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 17, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

IL-17 Signaling Inhibitors in Localized Scleroderma: A Single-Center Case Series of Nine Patients.

Takuya Takahashi1, Takehiro Takahashi1, Yuichiro Segawa1

  • 1Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

The Journal of Dermatology
|July 16, 2026
PubMed
Summary

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Clinical Interpretation of a Novel AAGAB Splice-Site Variant (c.73+5G>A) of Uncertain Significance in a Clinically Typical Punctate Palmoplantar Epidermal Differentiation Disorder Phenotype.

The Journal of dermatology·2026
Same author

Wound, Pressure Ulcer, and Burn Guidelines (2023)-6: Guidelines for the Management of Burns, Third Edition.

The Journal of dermatology·2026
Same author

Hypopigmented Mycosis Fungoides With Childhood-Onset and Middle-Aged Onset: Two Case Reports Focusing on the Cutaneous Immune Microenvironment.

The Journal of dermatology·2026
Same author

Clinical positioning and future prospects of JAK inhibitors in alopecia areata.

Expert opinion on pharmacotherapy·2026
Same author

Circumscribed Morphea Successfully Treated With Excimer Laser: Analysis of Histopathological Changes.

The Journal of dermatology·2026
Same author

Successful Control of Langer hans Cell Sarcoma in a Super-Aged Patient Using Intensity-Modulated Radiotherapy.

The Journal of dermatology·2026

Interleukin-17 (IL-17) pathway inhibitors show potential for treating severe localized scleroderma (LSc). While not definitive, these treatments offered improvement or stabilization in most patients refractory to traditional therapies.

Area of Science:

  • Dermatology
  • Immunology
  • Rheumatology

Background:

  • Localized scleroderma (LSc) is an autoimmune fibrosing condition impacting skin and soft tissues.
  • Current treatments for severe or refractory LSc are limited.
  • IL-17 signaling is associated with active inflammatory lesions in LSc.

Purpose of the Study:

  • To evaluate the outcomes of IL-17 pathway inhibitors in patients with refractory localized scleroderma.
  • To assess the safety and potential efficacy of IL-17A or IL-17 receptor A inhibitors in LSc management.

Main Methods:

  • Retrospective analysis of nine LSc patients treated with IL-17 inhibitors (ixekizumab, secukinumab, brodalumab).
  • Patients had disease refractory to conventional therapies or were predicted to have treatment resistance.
Keywords:
IL‐17AIL‐17RAbrodalumabixekizumablocalized sclerodermasecukinumab

Related Experiment Videos

Last Updated: Jul 17, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

  • Institutional approval was obtained for off-label drug use.

    • Main Results:

    • Five of nine patients showed improvement in their LSc.
    • Two patients experienced disease stabilization, while two patients showed progression.
    • One patient developed pustulotic arthro-osteitis, a potential paradoxical reaction; no other major adverse events were noted.

    Conclusions:

    • IL-17 pathway inhibition may offer a therapeutic option for selected patients with refractory localized scleroderma.
    • Further controlled studies are warranted to establish the efficacy and safety of these biologics in LSc.
    • These findings suggest IL-17 blockade is a promising avenue for LSc research.